

Stephane Ederhy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2774090/publications.pdf>

Version: 2024-02-01

115
papers

9,453
citations

159585

30
h-index

40979

93
g-index

133
all docs

133
docs citations

133
times ranked

12404
citing authors

#	ARTICLE	IF	CITATIONS
1	2017 ESC/EACTS Guidelines for the management of valvular heart disease. <i>European Heart Journal</i> , 2017, 38, 2739-2791.	2.2	5,142
2	Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity. <i>Circulation</i> , 2017, 136, 2085-2087.	1.6	364
3	Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer. <i>JAMA Oncology</i> , 2020, 6, 865.	7.1	295
4	Myocarditis in the Setting of Cancer Therapeutics. <i>Circulation</i> , 2019, 140, 80-91.	1.6	278
5	HIV and Coronary Heart Disease. <i>Journal of the American College of Cardiology</i> , 2013, 61, 511-523.	2.8	234
6	Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. <i>European Heart Journal</i> , 2020, 41, 1733-1743.	2.2	212
7	Pulmonary embolism in COVID-19 patients: a French multicentre cohort study. <i>European Heart Journal</i> , 2020, 41, 3058-3068.	2.2	209
8	Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis. <i>Journal of the American College of Cardiology</i> , 2020, 75, 467-478.	2.8	179
9	Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy. <i>Nature Communications</i> , 2017, 8, 16105.	12.8	175
10	Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio-Oncology Guidelines. <i>Journal of the American Heart Association</i> , 2020, 9, e018403.	3.7	149
11	Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor-Associated Myocarditis. <i>Circulation</i> , 2020, 141, 2031-2034.	1.6	142
12	Circulating Secretory Phospholipase A2 Activity and Risk of Incident Coronary Events in Healthy Men and Women. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 1177-1183.	2.4	99
13	Acute coronary syndrome in human immunodeficiency virus-infected patients: characteristics and 1 year prognosis. <i>European Heart Journal</i> , 2011, 32, 41-50.	2.2	99
14	Takotsubo-Like Syndrome in Cancer Patients Treated With Immune Checkpoint Inhibitors. <i>JACC: Cardiovascular Imaging</i> , 2018, 11, 1187-1190.	5.3	82
15	Subclinical Cardiac Abnormalities in Human Immunodeficiency Virus-Infected Men Receiving Antiretroviral Therapy. <i>American Journal of Cardiology</i> , 2008, 101, 1213-1217.	1.6	78
16	Levels of Circulating Procoagulant Microparticles in Nonvalvular Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2007, 100, 989-994.	1.6	60
17	Survival After Fulminant Myocarditis Induced by Immune-Checkpoint Inhibitors. <i>Annals of Internal Medicine</i> , 2017, 167, 683.	3.9	60
18	Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors. , 2019, 7, 53.		59

#	ARTICLE	IF	CITATIONS
19	Restoring Sinus Rhythm Reverses Cardiac Remodeling and Reduces Valvular Regurgitation in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2022, 79, 951-961.	2.8	55
20	Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors. , 2020, 8, e000261.		53
21	Early Cardiac Toxicity Associated With Post-Transplant Cyclophosphamide in Allogeneic Stem Cell Transplantation. <i>JACC: CardioOncology</i> , 2021, 3, 250-259.	4.0	48
22	High incidence of atrial fibrillation in patients treated with ibrutinib. <i>Open Heart</i> , 2019, 6, e001049.	2.3	45
23	Electrocardiographic Manifestations of Immune Checkpoint Inhibitor Myocarditis. <i>Circulation</i> , 2021, 144, 1521-1523.	1.6	44
24	Systematic analysis of drug-associated myocarditis reported in the World Health Organization pharmacovigilance database. <i>Nature Communications</i> , 2022, 13, 25.	12.8	44
25	Cardiac side effects of molecular targeted therapies: Towards a better dialogue between oncologists and cardiologists. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 80, 369-379.	4.4	43
26	Acute Coronary Syndrome With Immune Checkpoint Inhibitors: A Proof-of-Concept Case and Pharmacovigilance Analysis of a Life-Threatening Adverse Event. <i>Canadian Journal of Cardiology</i> , 2020, 36, 476-481.	1.7	40
27	Frequency and management of troponin I elevation in patients treated with molecular targeted therapies in phase I trials. <i>Investigational New Drugs</i> , 2012, 30, 611-615.	2.6	38
28	EACVI recommendations on cardiovascular imaging for the detection of embolic sources: endorsed by the Canadian Society of Echocardiography. <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 22, e24-e57.	1.2	38
29	Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health Organization pharmacovigilance study. <i>European Heart Journal</i> , 2021, 42, 3915-3928.	2.2	38
30	The 2016-2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study. <i>European Journal of Cancer</i> , 2020, 130, 39-50.	2.8	37
31	Electrocardiographic features of immune checkpoint inhibitor associated myocarditis. , 2021, 9, e002007.		36
32	Factors influencing the level of circulating procoagulant microparticles in acute pulmonary embolism. <i>Archives of Cardiovascular Diseases</i> , 2010, 103, 394-403.	1.6	35
33	Increased Risk of Left Heart Valve Regurgitation Associated With Benfluorex Use in Patients With Diabetes Mellitus. <i>Circulation</i> , 2012, 126, 2852-2858.	1.6	32
34	C-reactive protein and transesophageal echocardiographic markers of thromboembolism in patients with atrial fibrillation. <i>International Journal of Cardiology</i> , 2012, 159, 40-46.	1.7	32
35	Management and research in cancer treatment-related cardiovascular toxicity: Challenges and perspectives. <i>International Journal of Cardiology</i> , 2016, 224, 366-375.	1.7	32
36	Takotsubo syndrome in patients with cancer treated with immune checkpoint inhibitors: a new adverse cardiac complication. <i>European Journal of Heart Failure</i> , 2019, 21, 945-947.	7.1	32

#	ARTICLE	IF	CITATIONS
37	D-dimer at hospital admission for COVID-19 are associated with in-hospital mortality, independent of venous thromboembolism: Insights from a French multicenter cohort study. Archives of Cardiovascular Diseases, 2021, 114, 381-393.	1.6	31
38	QT interval prolongation among patients treated with angiogenesis inhibitors. Targeted Oncology, 2009, 4, 89-97.	3.6	30
39	Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept. , 2022, 10, e004699.		29
40	Effectiveness of Screening for Abdominal Aortic Aneurysm During Echocardiography. American Journal of Cardiology, 2014, 114, 1100-1104.	1.6	28
41	Consequences of obstructive sleep apnoea syndrome on left ventricular geometry and diastolic function. Archives of Cardiovascular Diseases, 2016, 109, 494-503.	1.6	25
42	Characteristics and outcomes of patients hospitalized for COVID-19 in France: The Critical COVID-19 France (CCF) study. Archives of Cardiovascular Diseases, 2021, 114, 352-363.	1.6	25
43	Circulating procoagulant microparticles in acute pulmonary embolism: A caseâ€“control study. International Journal of Cardiology, 2010, 145, 321-322.	1.7	24
44	Statin therapy and low-density lipoprotein cholesterol reduction in HIV-infected individuals after acute coronary syndrome: Results from the PACS-HIV lipids substudy. American Heart Journal, 2017, 183, 91-101.	2.7	24
45	Cardiotoxicity Associated with Gemcitabine: Literature Review and a Pharmacovigilance Study. Pharmaceuticals, 2020, 13, 325.	3.8	23
46	Cardiac Events Associated With Chimeric Antigen Receptor T-Cells (CAR-T). Journal of the American College of Cardiology, 2020, 75, 2521-2523.	2.8	23
47	Is von Willebrand factor associated with stroke and death at mid-term in patients with non-valvular atrial fibrillation?. Archives of Cardiovascular Diseases, 2018, 111, 357-369.	1.6	22
48	Management of Immune Checkpoint Inhibitorâ€“Induced Myocarditis. JACC: CardioOncology, 2021, 3, 157-161.	4.0	22
49	Prognostic value of right ventricular dilatation in patients with COVID-19: a multicentre study. European Heart Journal Cardiovascular Imaging, 2022, 23, 569-577.	1.2	22
50	Is the aortic root dilated in obstructive sleep apnoea syndrome?. Archives of Cardiovascular Diseases, 2008, 101, 391-397.	1.6	21
51	Left ventricular diastolic dysfunction in obstructive sleep apnoea syndrome by an echocardiographic standardized approach: An observational study. Archives of Cardiovascular Diseases, 2015, 108, 480-490.	1.6	19
52	Comparison of transesophageal echocardiographic identification of embolic risk markers in patients with lone versus nonâ€“lone atrial fibrillation. American Journal of Cardiology, 2005, 95, 592-596.	1.6	18
53	Left atrial volume is not an index of left ventricular diastolic dysfunction in patients with sickle cell anaemia. Archives of Cardiovascular Diseases, 2015, 108, 156-162.	1.6	18
54	Medication reconciliation: Predictors of risk of unintentional medication discrepancies in the cardiology department. Archives of Cardiovascular Diseases, 2019, 112, 104-112.	1.6	16

#	ARTICLE	IF	CITATIONS
55	Impaired myocardial deformation detected by speckle-tracking echocardiography in patients with myotonic dystrophy type 1. <i>International Journal of Cardiology</i> , 2011, 152, 375-376.	1.7	15
56	Role of multimodality imaging in the diagnosis and management of cardiomyopathies. <i>Archives of Cardiovascular Diseases</i> , 2019, 112, 615-629.	1.6	15
57	Impact of selective serotonin reuptake inhibitor therapy on heart valves in patients exposed to benfluorex: A multicentre study. <i>Archives of Cardiovascular Diseases</i> , 2013, 106, 349-356.	1.6	14
58	Relationship between Cognitive Impairment and Echocardiographic Parameters: A Review. <i>Journal of the American Society of Echocardiography</i> , 2015, 28, 264-274.	2.8	14
59	Frequency of drug-induced valvular heart disease in patients previously exposed to benfluorex: a multicentre prospective study. <i>European Heart Journal</i> , 2013, 34, 3580-3587.	2.2	13
60	Can we improve transthoracic echocardiography training in non-cardiologist residents? Experience of two training programs in the intensive care unit. <i>Annals of Intensive Care</i> , 2016, 6, 44.	4.6	13
61	Intermediate- vs. Standard-Dose Prophylactic Anticoagulation in Patients With COVID-19 Admitted in Medical Ward: A Propensity Score-Matched Cohort Study. <i>Frontiers in Medicine</i> , 2021, 8, 747527.	2.6	13
62	¹⁸ F-fluorodeoxyglucose positron emission tomography/computed tomography imaging for the diagnosis of immune checkpoint inhibitor-associated myocarditis. <i>Archives of Cardiovascular Diseases</i> , 2022, 115, 114-116.	1.6	13
63	Silent cardiac dysfunction and exercise intolerance in HIV+ men receiving combined antiretroviral therapies. <i>Aids</i> , 2008, 22, 2537-2540.	2.2	12
64	Decrease in Left Atrium Volume after Successful Balloon Mitral Valvuloplasty: An Echocardiographic and Hemodynamic Study. <i>Echocardiography</i> , 2011, 28, 154-160.	0.9	12
65	Non-vitamin K antagonist oral anticoagulants and heart failure. <i>Archives of Cardiovascular Diseases</i> , 2016, 109, 641-650.	1.6	12
66	Batrial remodelling in atrial fibrillation: A three-dimensional and strain echocardiography insight. <i>Archives of Cardiovascular Diseases</i> , 2019, 112, 585-593.	1.6	12
67	Does layer-specific strain using speckle tracking echocardiography improve the assessment of left ventricular myocardial deformation? A review. <i>Archives of Cardiovascular Diseases</i> , 2020, 113, 721-735.	1.6	12
68	D-dimers in atrial fibrillation: a further step in risk stratification of thrombo-embolism?. <i>European Heart Journal</i> , 2007, 28, 2179-2180.	2.2	11
69	Not All Patients with a Pancreatic Neuroendocrine Tumour Will Benefit from All Approved or Recommended Therapeutic Options: A Real-Life Retrospective Study. <i>Neuroendocrinology</i> , 2017, 105, 26-34.	2.5	11
70	Serum tryptophan-derived quinolinate and indole-3-acetate are associated with carotid intima-media thickness and its evolution in HIV-infected treated adults. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz516.	0.9	10
71	In-hospital outcomes and 5-year mortality following an acute myocardial infarction in patients with a history of cancer: Results from the French registry on Acute ST-elevation or non-ST-elevation myocardial infarction (FAST-MI) 2005 cohort. <i>Archives of Cardiovascular Diseases</i> , 2019, 112, 657-669.	1.6	10
72	Looking at New Unexpected Disease Targets in LMNA-Linked Lipodystrophies in the Light of Complex Cardiovascular Phenotypes: Implications for Clinical Practice. <i>Cells</i> , 2020, 9, 765.	4.1	10

#	ARTICLE	IF	CITATIONS
73	Determinants of clinical presentation on outcomes in older patients with myocardial infarction. <i>Geriatrics and Gerontology International</i> , 2018, 18, 1591-1596.	1.5	9
74	Correlation between left atrial spontaneous echocardiographic contrast and 5-year stroke/death in patients with non-valvular atrial fibrillation. <i>Archives of Cardiovascular Diseases</i> , 2020, 113, 525-533.	1.6	9
75	Role of Cardiac Imaging in the Diagnosis of Immune Checkpoints Inhibitors Related Myocarditis. <i>Frontiers in Oncology</i> , 2021, 11, 640985.	2.8	9
76	Multilayer global longitudinal strain in patients with cancer: A comparison of two vendors. <i>Archives of Cardiovascular Diseases</i> , 2018, 111, 285-296.	1.6	8
77	Should all patients with non-valvular atrial fibrillation be anticoagulated?. <i>International Journal of Cardiology</i> , 2010, 143, 8-15.	1.7	7
78	Food and Drug Administration criteria for the diagnosis of drug-induced valvular heart disease in patients previously exposed to benfluorex: a prospective multicentre study. <i>European Heart Journal Cardiovascular Imaging</i> , 2015, 16, 158-165.	1.2	7
79	Should we administrate anticoagulants to critically ill patients with new onset supraventricular arrhythmias?. <i>Archives of Cardiovascular Diseases</i> , 2015, 108, 217-219.	1.6	7
80	History of heart failure in patients with coronavirus disease 2019: Insights from a French registry. <i>Archives of Cardiovascular Diseases</i> , 2021, 114, 415-425.	1.6	7
81	Association of early electrical changes with cardiovascular outcomes in immune checkpoint inhibitor myocarditis. <i>Archives of Cardiovascular Diseases</i> , 2022, 115, 315-330.	1.6	7
82	Left ventricular ejection fraction: An additional risk marker in COVID-19. <i>Archives of Cardiovascular Diseases</i> , 2020, 113, 760-762.	1.6	6
83	Characterization and outcomes of acute myocardial injury in COVID-19 intensive care patients. <i>Infection</i> , 2021, 49, 563-566.	4.7	6
84	Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inhibitor to screen cardiac or neuromuscular immune-related toxicities. <i>European Journal of Cancer</i> , 2021, 157, 383-390.	2.8	6
85	Trastuzumab-Induced Cardiotoxicity. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012, 35, 183-184.	1.3	5
86	Characteristics and impact of cardiovascular comorbidities on coronavirus disease 2019 in women: A multicentre cohort study. <i>Archives of Cardiovascular Diseases</i> , 2021, 114, 394-406.	1.6	5
87	Immune Checkpoint Inhibitor Myocarditis With Normal Cardiac Magnetic Resonance Imaging: Importance of Cardiac Biopsy and Early Diagnosis. <i>Canadian Journal of Cardiology</i> , 2021, 37, 1654-1656.	1.7	5
88	Optimising stroke prevention in non-valvular atrial fibrillation. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 2079-2094.	1.8	4
89	Three-dimensional transesophageal echocardiography for descending aortic atheroma: a preliminary study. <i>International Journal of Cardiovascular Imaging</i> , 2014, 30, 1529-1537.	1.5	4
90	Letter to the editors-in-chief reply to: Solinas et al. Venous and arterial thromboembolic events with immune check point inhibitors: A systematic review. <i>Thrombosis Research</i> , 2021, 208, 214-216.	1.7	4

#	ARTICLE	IF	CITATIONS
91	Is Obstructive Sleep Apnea Associated With Greater Thoracic Aortic Size?. Journal of the American College of Cardiology, 2009, 53, 815.	2.8	3
92	Mechanisms of thrombogenesis in atrial fibrillation. Lancet, The, 2009, 373, 1005-1006.	13.7	3
93	Reversible cardiogenic shock following 5-Fluorouracil infusion. Investigational New Drugs, 2010, 28, 531-533.	2.6	3
94	Predictive factors of renal toxicities related to anti-VEGFR multikinase inhibitors in phase 1 trials. Investigational New Drugs, 2017, 35, 79-86.	2.6	3
95	Foreign body causing superficial venous thrombosis and subsequent pulmonary embolism: a case report. European Heart Journal - Case Reports, 2018, 2, yty125.	0.6	3
96	Improved Cardiac Outcomes by Early Treatment with Angiotensin-Converting Enzyme Inhibitors in Becker Muscular Dystrophy. Journal of Neuromuscular Diseases, 2021, 8, 495-502.	2.6	3
97	Re: Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials. European Journal of Cancer, 2021, 155, 299-302.	2.8	3
98	Transesophageal echocardiography for cardiovascular risk estimation in patients with sepsis and new-onset atrial fibrillation: a multicenter prospective pilot study. Annals of Intensive Care, 2021, 11, 146.	4.6	3
99	Coronary Angiographic Features and Major Adverse Cardiac or Cerebrovascular Events in People Living With Human Immunodeficiency Virus Presenting With Acute Coronary Syndrome. Circulation: Cardiovascular Interventions, 2022, 15, 101161CIRCINTERVENTIONS122011945.	3.9	3
100	Cardio-oncology: Clinical and imaging perspectives for optimal cardiodetection and cardioprotection in patients with cancer. Archives of Cardiovascular Diseases, 2019, 112, 550-558.	1.6	2
101	Tricuspid and pulmonary valve involvement in carcinoid heart disease. Archives of Cardiovascular Diseases, 2009, 102, 591-592.	1.6	1
102	Acute left ventricular dysfunction induced by a panHER and VEGFR tyrosine kinase inhibitor in a phase I trial. Investigational New Drugs, 2010, 28, 350-352.	2.6	1
103	Right ventricular systolic function assessment by echocardiography in routine clinical practice: Simple and feasible. Archives of Cardiovascular Diseases, 2014, 107, 505-507.	1.6	1
104	Simultaneous Left and Right Ventricular Thrombi Caused by Catastrophic Antiphospholipid Syndrome. American Journal of Respiratory and Critical Care Medicine, 2019, 200, e147-e149.	5.6	1
105	Cardiotoxicity Related to Immune Checkpoint Inhibitors. Current Treatment Options in Cardiovascular Medicine, 2021, 23, 1.	0.9	1
106	Troponin increase during immunotherapy: Not always myocarditis. European Journal of Cancer, 2021, 157, 424-427.	2.8	1
107	From cardio-oncology to cardio-onco-pharmacology: Towards a multidisciplinary approach in the understanding and management of cardiotoxicity. Therapie, 2022, 77, 197-206.	1.0	1
108	Echocardiography and renin-aldosterone interplay as predictors of death in COVID-19. Archives of Cardiovascular Diseases, 2022, 115, 96-96.	1.6	1

#	ARTICLE	IF	CITATIONS
109	Cardiac troponin I elevation and overall survival among cancer patients receiving investigational compounds during phase I trials. <i>International Journal of Cardiology</i> , 2016, 214, 364-369.	1.7	0
110	Response by Thuny et al to Letter Regarding Article, "Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity". <i>Circulation</i> , 2018, 137, 2423-2424.	1.6	0
111	Les cardiomyopathies toxiques liées aux chimiothérapies. <i>Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique</i> , 2018, 2018, 10-14.	0.0	0
112	How should we manage left atrial thrombosis?. <i>Archives of Cardiovascular Diseases</i> , 2020, 113, 587-589.	1.6	0
113	A tribute to Yves Juilliard, MD, PhD (1957 to 2021). <i>Archives of Cardiovascular Diseases</i> , 2021, 114, 261-267.	1.6	0
114	Factor Xa inhibitors or factor IIa inhibitors in atrial fibrillation?. <i>Sang Thrombose Vaisseaux</i> , 2013, 25, 19-33.	0.1	0
115	Natural history of left atrial thrombus in atrial fibrillation patients. <i>Sang Thrombose Vaisseaux</i> , 2016, 28, 262-273.	0.1	0